Investigations from Body Fluids in Non-Responding Empirical TB Treatment

Priority Investigations

The American Thoracic Society recommends collecting fresh specimens from all accessible body fluid sites for AFB smear microscopy, mycobacterial culture, and drug susceptibility testing before modifying the treatment regimen 3, 1
The European Respiratory Society suggests performing rapid molecular testing (genotypic rifampicin and isoniazid resistance testing) on all specimens using platforms like Xpert MTB/RIF or Xpert MTB/XDR 4, 2
The Infectious Diseases Society of America recommends sending isolates to a reference laboratory for comprehensive phenotypic DST to both first-line drugs and second-line drugs 1, 5

For pulmonary TB, the American Journal of Respiratory and Critical Care Medicine recommends collecting at least three sputum specimens on separate days for smear, culture, and molecular testing 6, 2
For pleural TB, the European Respiratory Journal suggests obtaining pleural fluid for AFB smear, culture, adenosine deaminase (ADA), and considering pleural biopsy for culture and histopathology 2
For meningeal TB, the European Respiratory Journal recommends collecting CSF for AFB smear, culture, biochemistry, and molecular testing 2
For peritoneal/ascitic TB, the European Respiratory Journal suggests aspirating ascitic fluid for AFB smear, culture, ADA levels, and cytology 2

The American Journal of Respiratory and Critical Care Medicine defines treatment failure as continued or recurrent positive cultures after 4 months of treatment, but evaluation should begin if cultures remain positive after 2-3 months 3, 1
The European Respiratory Journal recommends monthly sputum monitoring with smear and culture for MDR-TB cases in resource-adequate settings 4, 2

The Infectious Diseases Society of America advises never modifying treatment without obtaining specimens first, as this eliminates the opportunity to identify the causative organism and resistance pattern 1, 7
The American Journal of Respiratory and Critical Care Medicine recommends not relying solely on smear microscopy, as culture and DST are mandatory 6, 2
The American Thoracic Society suggests avoiding adding a single drug to a failing regimen while awaiting DST results, as this amplifies resistance; instead, add at least 2-3 new drugs empirically 3, 1, 7

The Infectious Diseases Society of America recommends assessing medication adherence through directly observed therapy records, pill counts, or therapeutic drug monitoring (TDM) if available 1, 7
The American Journal of Respiratory and Critical Care Medicine suggests evaluating for malabsorption by considering TDM in patients with gastrointestinal disease, prior gastric surgery, or concurrent antacid use 1, 7
The Clinical Infectious Diseases journal recommends screening for diabetes mellitus and gastroparesis, which can affect drug absorption and treatment response 1
The American Journal of Respiratory and Critical Care Medicine advises excluding alternative diagnoses, such as fungal infections, malignancy, or other bacterial infections, if TB cultures remain negative 6

The American Journal of Respiratory and Critical Care Medicine recommends initiating an empirical expanded regimen immediately containing at least 5 drugs if the patient is seriously ill or has positive AFB smears 3, 8, 7
The Infectious Diseases Society of America suggests that the empirical regimen should include drugs the patient has not received previously and to which the organism is likely susceptible based on regional resistance patterns and treatment history 3, 9, 5